(Q31143336)

English

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 June 2017

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials (English)

1 reference

Europe PubMed Central

29 June 2017

1 reference

based on heuristic

inferred from title

Dirk Schadendorf

6

0 references

4

0 references

Caroline Robert

5

object named as

Caroline Robert

0 references

Jean-Jacques Grob

2

object named as

Jean-Jacques Grob

0 references

Georgina V. Long

object named as

Georgina V Long

1

0 references

10

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

29 June 2017

author name string

Paul Nathan

3

1 reference

Europe PubMed Central

29 June 2017

Stephen R Lane

7

1 reference

Europe PubMed Central

29 June 2017

Carmen Mak

8

1 reference

Europe PubMed Central

29 June 2017

Philippe Legenne

9

1 reference

Europe PubMed Central

29 June 2017

Michael A Davies

11

1 reference

Europe PubMed Central

29 June 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

15 November 2016

1 reference

Europe PubMed Central

29 June 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

29 June 2017

17

1 reference

Europe PubMed Central

29 June 2017

12

1 reference

Europe PubMed Central

29 June 2017

1743-1754

1 reference

Europe PubMed Central

29 June 2017

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930578-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30578-2

1 reference

Europe PubMed Central

29 June 2017

1 reference

Europe PubMed Central

29 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31143336&oldid=1977304480"